SYGNIS obtains European and American patent for an innovative platform of very versatile and effective analysis of medicinal products.

-Detection of interactions protein has become an increasingly important method for the development of new drugs, because it simplifies testing and allows to analyze new drugs in a way absolutely innovative

-the new technology of SYGNIS extends the possibilities of innovative drugs with new mechanisms of action

-SYGNIS intends to award to another firm the license for the distribution of this technology

-SYGNIS completed its merger with the Spanish company X-Pol, a subsidiary of the GENETRIX group, in December of last year

Heidelberg, Madrid, January of 2013- the signing of biotechnology SYGNIS Pharma AG (Frankfurt: LIO1;) ISIN: DE000A1RFM03; Prime Standard) has obtained patents for Europe and the United States of a new technology for the detection of interactions between proteins, a novel platform of analysis for the development of new drugs. According to the CEO of SYGNIS, Pilar de la Huerta, we’ll give another signing the license for the distribution of this technology, and we hope our first revenue linked to this platform during the present fiscal year ”.

The study of protein-protein interactions belongs to the field of proteomics, becoming increasingly important in the investigation of new custom drugs. The new platform of SYGNIS can use to improve the characterization of new drugs in phase of development and discovery of new therapeutic targets. SYGNIS technology will increase the potential for the creation of new medicines within the scope of personalized medicine. After the merger with the Spanish firm X-POL, a subsidiary of the GENETRIX group, SYGNIS expected to become a key actor in the growing market of molecular tools and personalized medicine.

the CEO of SYGNIS, Pilar de la Huerta.

In addition to the recent restructuring of the company and the successful implementation of the polymerase Qualiphi ®, SYGNIS hoped to use these patents to give impetus to the merger with X-Pol and become a key piece within the growing market of DNA tools and personalized medicinesa sector that has experienced a growth of two digits in recent years. Sources of SYGNIS Pharma AG say that this transformation will enable them to obtain early 2013 revenues and operating profits in subsequent years.

about SYGNIS Pharma AG

SYGNIS Pharma AG (Heidelberg, Germany) is a biotechnology company that is listed on the Prime Standard of the bag of values of Germany segment with the LIO1 symbol; ISIN: DE000A1RFM03. According to the new business strategy defined in 2012, after the merger with the Spanish company X-Pol Biotech company is dedicated mainly to the development and distribution of new technologies of molecular biology, such as the amplification and sequencing of DNA. In July 2012 has signed an exclusive licensing agreement world with Qiagen to Qualiphi ®, an optimized version of the isotherm (phi-29) DNA amplification polymerase.